PCA3 useful for early diagnosis of prostate cancer
Based on a meta-analysis reported in the Chinese Medical Journal, prostate cancer antigen 3 (PCA3) can be used for the early diagnosis of prostate cancer and to avoid unnecessary biopsies, with a sensitivity of 0.82, a specificity of 0.962, a positive likelihood ratio of 2.39, a negative likelihood ratio of 0.51, and a diagnostic odds ratio of 4.89.
High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients
As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.
GALNT4 predicts survival in patients with ccRCC
As reported in the Journal of Urology, N-acetylgalactosaminyltransferase 4 (GALNT4) levels are decreased in tumor specimens from patients with clear cell renal cell carcinoma (ccRCC; n=104) compared to peritumoral specimens. Decreased expression of GALNT4 is associated with poor OS (OR=3.08) and RFS (OR=2.17). Further, GALNT4 is negatively correlated with tumor size, necrosis, and TNM stage.